



## Clinical trial results:

### A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

#### Summary

EudraCT number	2018-003811-23
Trial protocol	DE IT GB
Global end of trial date	08 March 2022

#### Results information

Result version number	v1 (current)
This version publication date	02 December 2023
First version publication date	02 December 2023
Summary attachment (see zip file)	Delayed Results Posting Memo (IMG-7289-CTP-102 _DRP Extension Memo for EU CTR.docx)

#### Trial information

##### Trial identification

Sponsor protocol code	IMG-7289-CTP-102
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03136185
WHO universal trial number (UTN)	-
Other trial identifiers	Merck Protocol Number: MK-3543-002

Notes:

#### Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 March 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 March 2022
Global end of trial reached?	Yes
Global end of trial date	08 March 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis.

The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 July 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 7
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	Hong Kong: 20
Country: Number of subjects enrolled	Italy: 13
Country: Number of subjects enrolled	United States: 37
Country: Number of subjects enrolled	United Kingdom: 9
Worldwide total number of subjects	90
EEA total number of subjects	17

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	37
From 65 to 84 years	52
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

Participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) were recruited for this study.

### Pre-assignment

Screening details:

Eighteen participants were enrolled in the Phase 1/2a portion of this study and 72 participants were enrolled in the Phase 2b portion of this study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d

Arm description:

In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 169 days during the Additional Treatment Period (ATP) as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d
------------------	--

Arm description:

In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
------------------	--

Arm description:

In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an

additional 169 days during the ATP as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
------------------	------------------------------------

Arm description:

In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d
------------------	---------------------------------------

Arm description:

In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
------------------	---------------------------------------

Arm description:

In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Arm description: In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Arm description: In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

<b>Arm title</b>	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Arm description: In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Arm type	Experimental
Investigational medicinal product name	Bomedemstat
Investigational medicinal product code	
Other name	IMG-7289 MK-3543 LSD1 inhibitor
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Oral (capsule) administration according to dose allocation.

Number of subjects in period 1	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Started	9	3	6
Completed Initial Treatment Period	7	3	4
Entered Additional Treatment Period	6	2	3
Completed	1	0	0
Not completed	8	3	6
Consent withdrawn by subject	1	-	1
Physician decision	3	1	1
Protocol Defined Disease Progression	-	-	1
Not Reported	4	1	-
Adverse event, non-fatal	-	1	3
Death	-	-	-

Number of subjects in period 1	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
Started	8	5	11
Completed Initial Treatment Period	4	1	4
Entered Additional Treatment Period	3	1	4
Completed	2	0	3
Not completed	6	5	8
Consent withdrawn by subject	1	1	1
Physician decision	2	1	2
Protocol Defined Disease Progression	-	-	1
Not Reported	1	-	2
Adverse event, non-fatal	1	2	2
Death	1	1	-

Number of subjects in period 1	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Started	24	11	13
Completed Initial Treatment Period	18	8	10
Entered Additional Treatment Period	17	5	9
Completed	14	5	7
Not completed	10	6	6
Consent withdrawn by subject	2	3	3
Physician decision	1	-	1
Protocol Defined Disease Progression	-	1	1
Not Reported	1	1	-
Adverse event, non-fatal	5	1	1

Death	1	-	-
-------	---	---	---



## Baseline characteristics

### Reporting groups

Reporting group title	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 169 days during the Additional Treatment Period (ATP) as determined by the investigator.	
Reporting group title	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	

Reporting group values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Number of subjects	9	3	6

Age categorical Units: Subjects			
Adults (18-64 years)	6	0	2
From 65-84 years	2	3	4
85 years and over	1	0	0
Age Continuous Units: Years			
arithmetic mean	62.6	74.7	64.7
standard deviation	± 12.43	± 5.51	± 6.59
Sex: Female, Male Units: Participants			
Female	1	0	4
Male	8	3	2
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	8	3	5
Unknown or Not Reported	1	0	0
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Black or African American	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	7	2	6
Other	1	1	0
Multiple	0	0	0
Not Reported	1	0	0

<b>Reporting group values</b>	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
Number of subjects	8	5	11
Age categorical Units: Subjects			
Adults (18-64 years)	2	2	3
From 65-84 years	6	3	8
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	69.6	64.8	69.4
standard deviation	± 8.38	± 7.46	± 14.40
Sex: Female, Male Units: Participants			
Female	4	4	6
Male	4	1	5
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	8	4	10
Unknown or Not Reported	0	1	0

Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Black or African American	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
White	7	4	9
Other	0	0	0
Multiple	0	0	0
Not Reported	1	0	1

Reporting group values	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Number of subjects	24	11	13
Age categorical Units: Subjects			
Adults (18-64 years)	11	4	7
From 65-84 years	13	7	6
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	65.2	66.7	61.3
standard deviation	± 9.42	± 9.27	± 12.07
Sex: Female, Male Units: Participants			
Female	12	8	4
Male	12	3	9
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	0	0
Not Hispanic or Latino	22	11	9
Unknown or Not Reported	1	0	4
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	10	5	5
Black or African American	0	0	1
Native Hawaiian or Other Pacific Islander	1	0	0
White	12	6	6
Other	0	0	0
Multiple	0	0	1
Not Reported	1	0	0

Reporting group values	Total		
Number of subjects	90		
Age categorical Units: Subjects			
Adults (18-64 years)	37		
From 65-84 years	52		
85 years and over	1		

Age Continuous Units: Years arithmetic mean standard deviation	-		
Sex: Female, Male Units: Participants			
Female	43		
Male	47		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	3		
Not Hispanic or Latino	80		
Unknown or Not Reported	7		
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0		
Asian	21		
Black or African American	2		
Native Hawaiian or Other Pacific Islander	1		
White	59		
Other	2		
Multiple	1		
Not Reported	4		

## End points

### End points reporting groups

Reporting group title	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 169 days during the Additional Treatment Period (ATP) as determined by the investigator.	
Reporting group title	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Reporting group description: In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Reporting group title	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Reporting group description: In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	
Subject analysis set title	Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d
Subject analysis set type	Safety analysis
Subject analysis set description: In the Phase 1/2a portion of the study, participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.	

## Primary: Number of Participants with Dose Limiting Toxicities (DLTs)

End point title	Number of Participants with Dose Limiting Toxicities (DLTs) <sup>[1]</sup>
-----------------	--

End point description:

DLT was defined as any one of the following adverse events (AEs) occurring through Day 7 of the ITP and considered by the Investigator to be possibly, probably or definitely related to bomedemstat: thrombocytopenia leading to clinically significant sequelae; a clinically significant bleeding event in a participant with a platelet count  $>50 \times 10^9/L$  (50 k/ $\mu$ L); any Grade 4 or 5 non-haematologic adverse event; any Grade 3 non-haematologic adverse event with failure to recover to Grade 2 within 7 days of drug cessation, with the following exceptions:  $\geq$  Grade 3 nausea, vomiting or diarrhea that responds to standard medical care;  $\geq$  Grade 3 asthenia lasting less than 14 days; any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. The number of participants with a DLT were reported. All allocated participants receiving  $\geq 1$  dose of bomedemstat were included in the DLT analysis.

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 7 of the ITP

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	3	6	8
Units: Participants	0	0	0	0

End point values	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	11	24	11
Units: Participants	0	0	0	0

End point values	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: Participants	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Serious Adverse Events

End point title	Number of Participants with Serious Adverse Events <sup>[2]</sup>
End point description:	
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. Serious AEs (SAEs) were any AE that resulted in death, life-threatening experience, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, or important medical events. The number of participants with at least one treatment-emergent (TE) SAE was reported for each arm. All allocated participants receiving at least one dose of bomedemstat were included in the safety analysis.	
End point type	Primary
End point timeframe:	
Up to approximately 30 months	
Notes:	
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: No statistical analyses were planned for this endpoint.	

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	3	6	8
Units: Participants	4	2	5	4

End point values	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	11	24	11
Units: Participants	4	7	12	3

End point values	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: Participants	3			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Adverse Events

End point title	Number of Participants with Adverse Events <sup>[3]</sup>
End point description:	
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any	

untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants with at least one TE AE was reported for each arm. All allocated participants receiving at least one dose of bomedemstat were included in the safety analysis.

End point type	Primary
End point timeframe:	
Up to approximately 30 months	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	3	6	8
Units: Participants	9	3	6	8

End point values	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	11	24	11
Units: Participants	5	11	23	10

End point values	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: Participants	12			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants that Discontinued Study Treatment Due To AEs

End point title	Number of Participants that Discontinued Study Treatment Due To AEs <sup>[4]</sup>
-----------------	--

End point description:

An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants that discontinued study treatment with bomedemstat due to a TE AE was reported for each arm. All allocated participants receiving at least one dose of bomedemstat were included in the safety analysis.

End point type	Primary
----------------	---------



End point timeframe:

Up to approximately 29 months

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	3	6	8
Units: Participants	0	1	5	1

End point values	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	11	24	11
Units: Participants	2	4	5	2

End point values	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: Participants	3			

## Statistical analyses

No statistical analyses for this end point

### Primary: Phase 1/2a Portion: Observed Maximum Concentration (C<sub>max</sub>) of Bomedemstat

End point title	Phase 1/2a Portion: Observed Maximum Concentration (C <sub>max</sub> ) of Bomedemstat <sup>[5][6]</sup>
-----------------	---

End point description:

C<sub>max</sub> was defined as the maximum observed concentration after administration obtained directly from the concentration time profile. Blood and plasma samples were collected at pre-specified timepoints to calculate C<sub>max</sub> in participants of the Phase 1/2a portion of the study. As pre-specified by the Pharmacokinetic Analysis Plan (PAP), all participants in the Phase 1/2a portion of the study who received bomedemstat and completed a sufficient portion of the study with enough data for the determination of pharmacokinetic parameters were analyzed. For the purposes of the analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder (PMF, PPV-MF, or PET-MF). As pre-specified by the protocol and PAP, Phase 2b participants were excluded from this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder. Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[7]</sup>	0 <sup>[8]</sup>	0 <sup>[9]</sup>	0 <sup>[10]</sup>
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	()	()
Blood	()	()	()	()

Notes:

[7] - Phase 2b participants were excluded from this analysis.

[8] - Phase 2b participants were excluded from this analysis.

[9] - Phase 2b participants were excluded from this analysis.

[10] - Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d	Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	0 <sup>[11]</sup>	0 <sup>[12]</sup>	12 <sup>[13]</sup>	
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	12.63 (± 104.41)	
Blood	()	()	26.27 (± 66.76)	

Notes:

[11] - Phase 2b participants were excluded from this analysis.

[12] - Phase 2b participants were excluded from this analysis.

[13] - For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder.

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of Bomedemstat

End point title	Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of Bomedemstat <sup>[14][15]</sup>
-----------------	---

End point description:

Tmax was defined as the time to maximum concentration after administration obtained by inspection. Blood and plasma samples were collected at pre-specified timepoints to calculate Tmax in participants of the Phase 1/2a portion of the study. As pre-specified by the PAP, all participants in the Phase 1/2a portion of the study who received bomedemstat and completed a sufficient portion of the study with enough data for the determination of pharmacokinetic parameters were analyzed. For the purposes of the analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder (PMF, PPV-MF,

or PET-MF). As pre-specified by the protocol and PAP, Phase 2b participants were excluded from this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder. Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[16]</sup>	0 <sup>[17]</sup>	0 <sup>[18]</sup>	0 <sup>[19]</sup>
Units: hour				
median (full range (min-max))				
Plasma	( to )	( to )	( to )	( to )
Blood	( to )	( to )	( to )	( to )

Notes:

[16] - Phase 2b participants were excluded from this analysis.

[17] - Phase 2b participants were excluded from this analysis.

[18] - Phase 2b participants were excluded from this analysis.

[19] - Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d	Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	0 <sup>[20]</sup>	0 <sup>[21]</sup>	12 <sup>[22]</sup>	
Units: hour				
median (full range (min-max))				
Plasma	( to )	( to )	1.00 (0.50 to 2.85)	
Blood	( to )	( to )	1.05 (0.50 to 3.02)	

Notes:

[20] - Phase 2b participants were excluded from this analysis.

[21] - Phase 2b participants were excluded from this analysis.

[22] - For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder.

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat from Time 0 to 24 hours post-dose (AUC0-24)

End point title	Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat from Time 0 to 24 hours post-dose (AUC0-24) <sup>[23][24]</sup>
-----------------	--

**End point description:**

AUC0-24 was defined as the area under the concentration versus time curve calculated using the linear trapezoidal rule from the zero time-point to the 24-hour time-point concentration. Blood and plasma samples were collected at pre-specified timepoints to calculate AUC0-24 in participants of the Phase 1/2a portion of the study. As pre-specified by the PAP, all participants in the Phase 1/2a portion of the study who received bomedemstat and completed a sufficient portion of the study with enough data for the determination of pharmacokinetic parameters were analyzed. For the purposes of the analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder (PMF, PPV-MF, or PET-MF). As pre-specified by the protocol and PAP, Phase 2b participants were excluded from this analysis.

End point type	Primary
----------------	---------

**End point timeframe:**

Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.

**Notes:**

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder. Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[25]</sup>	0 <sup>[26]</sup>	0 <sup>[27]</sup>	0 <sup>[28]</sup>
Units: hour•ng/mL				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	()	()
Blood	()	()	()	()

**Notes:**

[25] - Phase 2b participants were excluded from this analysis.

[26] - Phase 2b participants were excluded from this analysis.

[27] - Phase 2b participants were excluded from this analysis.

[28] - Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d	Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	0 <sup>[29]</sup>	0 <sup>[30]</sup>	12 <sup>[31]</sup>	
Units: hour•ng/mL				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	63.90 (± 68.56)	
Blood	()	()	265.92 (± 68.92)	

**Notes:**

[29] - Phase 2b participants were excluded from this analysis.

[30] - Phase 2b participants were excluded from this analysis.

[31] - For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder.

**Statistical analyses**

**Primary: Phase 1/2a Portion: Apparent total clearance (CL/F) of Bomedemstat after oral administration**

End point title	Phase 1/2a Portion: Apparent total clearance (CL/F) of Bomedemstat after oral administration <sup>[32][33]</sup>
-----------------	--

## End point description:

CL/F was defined as the apparent total clearance of drug after oral administration. Blood and plasma samples were collected at pre-specified timepoints to calculate CL/F in participants of the Phase 1/2a portion of the study. As pre-specified by the PAP, all participants in the Phase 1/2a portion of the study who received bomedemstat and completed a sufficient portion of the study with enough data for the determination of pharmacokinetic parameters were analyzed. For the purposes of the analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder (PMF, PPV-MF, or PET-MF). As pre-specified by the protocol and PAP, Phase 2b participants were excluded from this analysis.

End point type	Primary
----------------	---------

## End point timeframe:

Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.

## Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder. Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[34]</sup>	0 <sup>[35]</sup>	0 <sup>[36]</sup>	0 <sup>[37]</sup>
Units: mL/min				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	()	()
Blood	()	()	()	()

## Notes:

[34] - Phase 2b participants were excluded from this analysis.

[35] - Phase 2b participants were excluded from this analysis.

[36] - Phase 2b participants were excluded from this analysis.

[37] - Phase 2b participants were excluded from this analysis.

End point values	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d	Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	0 <sup>[38]</sup>	0 <sup>[39]</sup>	12 <sup>[40]</sup>	
Units: mL/min				
geometric mean (geometric coefficient of variation)				
Plasma	()	()	12787.43 (± 63.72)	
Blood	()	()	3067.57 (± 85.78)	

Notes:

[38] - Phase 2b participants were excluded from this analysis.

[39] - Phase 2b participants were excluded from this analysis.

[40] - For this analysis, Phase 1/2a participants were analyzed irrespective of myelofibrosis disorder.

## Statistical analyses

No statistical analyses for this end point

### Primary: Percent Change from Baseline in Spleen Volume

End point title	Percent Change from Baseline in Spleen Volume <sup>[41]</sup>
-----------------	---

End point description:

Change in spleen volume was to be assessed based on calculated spleen volume (ml) measured by magnetic resonance imaging (MRI), or computerized tomography (CT) scan (where locally permitted) if the participant was not a candidate for MRI from Day 0. Percent change from baseline in spleen volume was reported at Initial Treatment Period (ITP) Day 84, ITP Day 168, Additional Treatment Period 1 (ATP1) Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337). All allocated participants who received  $\geq 1$  dose of treatment and had available spleen volume data were analyzed. Due to differing dosing schedules, time points not applicable for certain arms or with no data collected are indicated by "0000" in the table (zero participants analyzed). 95% confidence intervals for arms with  $n > 2$  participants but where  $n < 2$  participants were evaluated at a time point are indicated as not evaluable with (-9999,9999) in the table.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical analyses were performed for this endpoint.

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 <sup>[42]</sup>	3 <sup>[43]</sup>	2 <sup>[44]</sup>	5 <sup>[45]</sup>
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	3.3 (-50.5 to 57.0)	-13.7 (-49.6 to 22.2)	2.2 (-110.3 to 114.8)	-9.1 (-27.9 to 9.6)
ITP Day 168 (Study Day 168)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	-23.9 (-43.2 to -4.6)
ATP1 Day 84 (Study Day 253)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)
ATP1 Day 168 (Study Day 337)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	-36.5 (-9999 to 9999)

Notes:

[42] - 0000=no participants analyzed. -9999/9999= not evaluable

[43] - 0000=no participants analyzed. -9999/9999= not evaluable

[44] - 0000=no participants analyzed. -9999/9999= not evaluable

[45] - 0000=no participants analyzed. -9999/9999= not evaluable

End point values	Ph 2b PPV-MF: Bomedemstat	Ph 2b PET-MF: Bomedemstat	Ph 2b PMF: Bomedemstat	Ph 2b PPV-MF: Bomedemstat
------------------	------------------------------	------------------------------	---------------------------	------------------------------

	0.5 mg/kg/d	0.5 mg/kg/d	0.6 mg/kg/d	0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 <sup>[46]</sup>	6 <sup>[47]</sup>	17 <sup>[48]</sup>	8 <sup>[49]</sup>
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	-7.2 (-80.2 to 65.8)	0.3 (-32.3 to 32.9)	10.0 (1.2 to 18.8)	-2.3 (-31.5 to 26.9)
ITP Day 168 (Study Day 168)	-19.6 (-9999 to 9999)	-33.7 (-43.8 to -23.6)	12.3 (-4.1 to 28.6)	-15.4 (-56.7 to 25.8)
ATP1 Day 84 (Study Day 253)	0000 (0000 to 0000)	-27.7 (-9999 to 9999)	0000 (0000 to 0000)	0000 (0000 to 0000)
ATP1 Day 168 (Study Day 337)	0000 (0000 to 0000)	-38.9 (-9999 to 9999)	37.4 (-55.6 to 130.5)	6.0 (-302.0 to 313.9)

Notes:

[46] - 0000=no participants analyzed. -9999/9999= not evaluable

[47] - 0000=no participants analyzed. -9999/9999= not evaluable

[48] - 0000=no participants analyzed. -9999/9999= not evaluable

[49] - 0000=no participants analyzed. -9999/9999= not evaluable

End point values	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[50]</sup>			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	1.2 (-10.9 to 13.2)			
ITP Day 168 (Study Day 168)	-4.4 (-20.6 to 11.8)			
ATP1 Day 84 (Study Day 253)	0000 (0000 to 0000)			
ATP1 Day 168 (Study Day 337)	-15.0 (-39.0 to 9.0)			

Notes:

[50] - 0000=no participants analyzed. -9999/9999= not evaluable

## Statistical analyses

No statistical analyses for this end point

## Primary: Percent Change from Baseline in Spleen Size

End point title	Percent Change from Baseline in Spleen Size <sup>[51]</sup>
End point description:	
Change in spleen size assessed based on spleen palpation (in cm) at each visit. Percent change from baseline in spleen size was reported at ITP Day 84, ITP Day 168, ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591). As prespecified by the Statistical Analysis Plan, assessments for Phase 1/2 groups summarized using visit windowing after the Day 84 visit of the ITP to allow for comparison with the Phase 2b groups at ITP Day 168. All allocated participants who received $\geq 1$ dose of treatment and had available spleen size data were analyzed. Due to differing dosing schedules, time points not applicable for certain arms or with no data collected are indicated by "0000" in the table (zero participants analyzed). 95% confidence intervals for arms with $n > 2$ participants but where $n < 2$ participants were evaluated at a time point are indicated as not evaluable with (-9999,9999) in the table.	
End point type	Primary

End point timeframe:

Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No between-group statistical analyses were performed for this endpoint.

End point values	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV- MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET- MF: Bomedemstat 0.25 mg/kg/d	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6 <sup>[52]</sup>	3 <sup>[53]</sup>	4 <sup>[54]</sup>	3 <sup>[55]</sup>
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	-36.5 (-68.0 to -5.0)	9.6 (-95.1 to 114.2)	24.1 (-79.4 to 127.7)	20.7 (-132.2 to 173.7)
ITP Day 168 (Study Day 168)	-20.7 (-48.3 to 6.9)	-39.6 (-9999 to 9999)	116.3 (-1794.8 to 2027.4)	-27.8 (-9999 to 9999)
ATP1 Day 84 (Study Day 253)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	-27.8 (-9999 to 9999)
ATP1 Day 168 (Study Day 337)	-19.0 (-9999 to 9999)	0000 (0000 to 0000)	0000 (0000 to 0000)	-27.8 (-9999 to 9999)
ATP2 Day 84 (Study Day 422)	-4.8 (-9999 to 9999)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)
ATP2 Day 168 (Study Day 506)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)
ATP3 Day 84 (Study Day 591)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)	0000 (0000 to 0000)

Notes:

[52] - 0000=no participants analyzed. -9999/9999= not evaluable

[53] - 0000=no participants analyzed. -9999/9999= not evaluable

[54] - 0000=no participants analyzed. -9999/9999= not evaluable

[55] - 0000=no participants analyzed. -9999/9999= not evaluable

End point values	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2 <sup>[56]</sup>	6 <sup>[57]</sup>	13 <sup>[58]</sup>	6 <sup>[59]</sup>
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	-28.1 (-257.8 to 201.6)	11.0 (-70.7 to 92.7)	-34.7 (-58.1 to -11.3)	-38.2 (-53.4 to -23.1)
ITP Day 168 (Study Day 168)	0000 (0000 to 0000)	-36.1 (-212.6 to 140.4)	-24.8 (-74.2 to 24.5)	-28.5 (-60.1 to 3.0)
ATP1 Day 84 (Study Day 253)	0000 (0000 to 0000)	-36.1 (-212.6 to 140.4)	-27.9 (-84.8 to 29.0)	-50.4 (-101.7 to 0.9)
ATP1 Day 168 (Study Day 337)	0000 (0000 to 0000)	-38.9 (-180.1 to 102.3)	-1.9 (-151.0 to 147.3)	-38.9 (-9999 to 9999)
ATP2 Day 84 (Study Day 422)	0000 (0000 to 0000)	-37.5 (-196.3 to 121.3)	0000 (0000 to 0000)	-44.4 (-9999 to 9999)
ATP2 Day 168 (Study Day 506)	0000 (0000 to 0000)	-22.0 (-9999 to 9999)	0000 (0000 to 0000)	0000 (0000 to 0000)
ATP3 Day 84 (Study Day 591)	0000 (0000 to 0000)	-11.1 (-152.3 to 130.1)	0000 (0000 to 0000)	0000 (0000 to 0000)



Notes:

[56] - 0000=no participants analyzed. -9999/9999= not evaluable

[57] - 0000=no participants analyzed. -9999/9999= not evaluable

[58] - 0000=no participants analyzed. -9999/9999= not evaluable

[59] - 0000=no participants analyzed. -9999/9999= not evaluable

<b>End point values</b>	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d			
Subject group type	Reporting group			
Number of subjects analysed	5 <sup>[60]</sup>			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
ITP Day 84 (Study Day 84)	-59.6 (-113.4 to -5.7)			
ITP Day 168 (Study Day 168)	-41.2 (-102.9 to 20.6)			
ATP1 Day 84 (Study Day 253)	-28.4 (-97.7 to 40.9)			
ATP1 Day 168 (Study Day 337)	-82.4 (-117.4 to -47.4)			
ATP2 Day 84 (Study Day 422)	0000 (0000 to 0000)			
ATP2 Day 168 (Study Day 506)	0000 (0000 to 0000)			
ATP3 Day 84 (Study Day 591)	0000 (0000 to 0000)			

Notes:

[60] - 0000=no participants analyzed. -9999/9999= not evaluable

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to approximately 30 months

Adverse event reporting additional description:

All-Cause Mortality table includes all allocated participants. Serious and Non-serious adverse events (AEs) tables include all allocated participants who received at least 1 dose of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d
-----------------------	---------------------------------------

Reporting group description:

In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 169 days during the Additional Treatment Period (ATP) as determined by the investigator.

Reporting group title	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d
-----------------------	--

Reporting group description:

In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
-----------------------	--

Reporting group description:

In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
-----------------------	------------------------------------

Reporting group description:

In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d
-----------------------	---------------------------------------

Reporting group description:

In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
-----------------------	------------------------------------

Reporting group description:

In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
-----------------------	---------------------------------------

Reporting group description:

In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
-----------------------	---------------------------------------

Reporting group description:

In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

Reporting group title	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
-----------------------	---------------------------------------

## Reporting group description:

In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during the ATP as determined by the investigator.

<b>Serious adverse events</b>	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 9 (44.44%)	2 / 3 (66.67%)	5 / 6 (83.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 9 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Thrombocytopenia			
subjects affected / exposed	2 / 9 (22.22%)	1 / 3 (33.33%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ear and labyrinth disorders</b>			
Vertigo			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Abdominal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	2 / 3 (66.67%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	2 / 3 (66.67%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pyoderma gangrenosum			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	2 / 9 (22.22%)	1 / 3 (33.33%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Clostridium difficile colitis			



subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 9 (11.11%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypervolaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 8 (50.00%)	4 / 5 (80.00%)	12 / 23 (52.17%)
number of deaths (all causes)	1	1	1
number of deaths resulting from adverse events	1	1	1
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	4 / 8 (50.00%)	2 / 5 (40.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 10	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory failure			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 8 (12.50%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Post procedural complication subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Headache			
subjects affected / exposed	1 / 8 (12.50%)	2 / 5 (40.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	4 / 8 (50.00%)	2 / 5 (40.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 26	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	2 / 8 (25.00%)	2 / 5 (40.00%)	2 / 23 (8.70%)
occurrences causally related to treatment / all	0 / 20	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 8 (25.00%)	1 / 5 (20.00%)	4 / 23 (17.39%)
occurrences causally related to treatment / all	0 / 2	0 / 1	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 8 (12.50%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pyoderma gangrenosum			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	1 / 8 (12.50%)	1 / 5 (20.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 5 (40.00%)	3 / 23 (13.04%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Clostridium difficile colitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Erysipelas			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 8 (37.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			

subjects affected / exposed	0 / 8 (0.00%)	1 / 5 (20.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypervolaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Ph 2b PET-MF:	Ph 2b PPV-MF:	Ph 2b PET-MF:
-------------------------------	---------------	---------------	---------------

	Bomedemstat 0.5 mg/kg/d	Bomedemstat 0.6 mg/kg/d	Bomedemstat 0.6 mg/kg/d
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 11 (63.64%)	3 / 10 (30.00%)	3 / 12 (25.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Atrial fibrillation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Thrombocytopenia			
subjects affected / exposed	7 / 11 (63.64%)	3 / 10 (30.00%)	3 / 12 (25.00%)
occurrences causally related to treatment / all	0 / 25	0 / 13	1 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	5 / 11 (45.45%)	2 / 10 (20.00%)	2 / 12 (16.67%)
occurrences causally related to treatment / all	0 / 26	0 / 3	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Faecaloma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			



Cholecystitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pyoderma gangrenosum			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Clostridium difficile colitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spontaneous bacterial peritonitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypervolaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d	Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	0 / 3 (0.00%)	6 / 6 (100.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Orthostatic hypotension			

subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	5 / 9 (55.56%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	6	0	4
Chest discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypothermia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Non-cardiac chest pain			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Peripheral swelling			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Oedema peripheral			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	4	0	1
Thirst			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Reproductive system and breast disorders			
Genital rash			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Diaphragmalgia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Dyspnoea			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	2	0	3
Dysphonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	4
Sleep apnoea syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	2
Respiratory failure			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pulmonary oedema			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sneezing			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Confusional state			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dysphoria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Flat affect			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Phonophobia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1



Sleep disorder subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Sleep terror subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Suicidal ideation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blast cell count increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blood calcium decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac murmur			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Troponin T increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	2
Cataract operation complication			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eye contusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Humerus fracture			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural swelling			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Periorbital haemorrhage			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Post procedural complication			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural haemorrhage			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscle strain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Soft tissue injury subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders			
Aortic valve incompetence subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 3	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiomegaly subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac failure subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Cardiac failure congestive subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac valve disease subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiopulmonary failure subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Tachycardia			

subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pericardial effusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Hypersomnia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	2
Dysgeusia			
subjects affected / exposed	6 / 9 (66.67%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	7	0	6
Dizziness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Amnesia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Peroneal nerve palsy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Parosmia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Parkinson's disease			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Neuralgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nerve compression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Presyncope			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Restless legs syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Sciatica			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Toxic encephalopathy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 9 (55.56%)	0 / 3 (0.00%)	4 / 6 (66.67%)
occurrences (all)	7	0	10
Leukocytosis			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	3
Splenomegaly			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Lymphopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	4	0	2
Lymphadenopathy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	5 / 9 (55.56%)	0 / 3 (0.00%)	4 / 6 (66.67%)
occurrences (all)	9	0	19
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Tinnitus			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Vertigo			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Photophobia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Conjunctival haemorrhage			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eye oedema			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Photopsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	1	0	4
Diarrhoea			
subjects affected / exposed	4 / 9 (44.44%)	0 / 3 (0.00%)	5 / 6 (83.33%)
occurrences (all)	5	0	6
Abdominal pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Abdominal pain lower			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
Constipation			
subjects affected / exposed	3 / 9 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0



Abdominal mass			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Gingival bleeding			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hiatus hernia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lip haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Oral mucosal blistering			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	5
Odynophagia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lip ulceration			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Retroperitoneal haematoma			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Tongue discolouration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Small intestinal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Toothache			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Ecchymosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Granulomatous dermatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Koilonychia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			

subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Onychalgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	4	0	1
Nail dystrophy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rash macular			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Rash pruritic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Skin mass			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Haematuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Arthralgia			
subjects affected / exposed	4 / 9 (44.44%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	9	0	5
Bursitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			

subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Myalgia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Neck pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Osteitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vertebral osteophyte			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal stenosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			

subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 5	0 / 3 (0.00%) 0	1 / 6 (16.67%) 2
Infections and infestations			
Appendicitis perforated			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	4	0	2
Clostridium difficile colitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Atypical pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Erysipelas			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Gastroenteritis viral			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gingivitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Gastroenteritis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Lower respiratory tract infection			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Nasal herpes			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Onychomycosis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sepsis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	2 / 9 (22.22%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0



Septic shock			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral pericarditis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	2
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	3	0	2
Hypernatraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hyperkalaemia			

subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	2
Hypermagnesaemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gout			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	2	0	6
Hyponatraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
Hypophosphataemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Lactic acidosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Increased appetite			
subjects affected / exposed	0 / 9 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Ph 2b PMF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)	0 / 5 (0.00%)	23 / 23 (100.00%)
Vascular disorders			

Hypertension			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Hot flush			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Pallor			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Generalised oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	4	0	2
Chest discomfort			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Hypothermia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	2	0	6
Oedema peripheral			
subjects affected / exposed	4 / 8 (50.00%)	0 / 5 (0.00%)	4 / 23 (17.39%)
occurrences (all)	10	0	6
Thirst			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Genital rash			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Diaphragmalgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	2	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Haemoptysis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	3	0	1
Dysphonia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	3	0	2
Sleep apnoea syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Respiratory failure			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dysphoria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0

Delirium			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Flat affect			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Phonophobia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sleep terror			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Alanine aminotransferase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Blast cell count increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			

subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	3	0	0
Blood calcium decreased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Blood creatinine increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	4
Blood glucose increased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Blood phosphorus decreased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Blood potassium decreased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Blood sodium decreased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Prothrombin time prolonged			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Body temperature increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiac murmur			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			



subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	2	0	2
Troponin T increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	1	0	4
Cataract operation complication			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Humerus fracture			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Post procedural swelling			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Periorbital haemorrhage			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Soft tissue injury			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Aortic valve incompetence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiomegaly			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiac failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiac failure congestive			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Cardiac valve disease			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0

Bradycardia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Cardiopulmonary failure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Ventricular extrasystoles			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	3	0	1
Pericardial effusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Hypersomnia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Dysgeusia			
subjects affected / exposed	3 / 8 (37.50%)	0 / 5 (0.00%)	6 / 23 (26.09%)
occurrences (all)	3	0	8
Dizziness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Amnesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Peroneal nerve palsy			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Parosmia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Parkinson's disease			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Nerve compression			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Restless legs syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sinus headache			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Toxic encephalopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	5 / 23 (21.74%)
occurrences (all)	20	0	5
Leukocytosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Splenomegaly			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Neutropenia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	1	0	3
Lymphadenopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	7 / 8 (87.50%)	0 / 5 (0.00%)	4 / 23 (17.39%)
occurrences (all)	29	0	11
Ear and labyrinth disorders			
Ear pain			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Photophobia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Eye oedema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Blepharitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Photopsia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	0	0	3
Abdominal distension			

subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	3 / 8 (37.50%)	0 / 5 (0.00%)	9 / 23 (39.13%)
occurrences (all)	3	0	12
Abdominal pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	1	0	4
Abdominal pain lower			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	4 / 23 (17.39%)
occurrences (all)	3	0	5
Abdominal mass			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Hiatus hernia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Lip haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Oral mucosal blistering			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	5 / 8 (62.50%)	0 / 5 (0.00%)	7 / 23 (30.43%)
occurrences (all)	5	0	11
Odynophagia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Lip ulceration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Retroperitoneal haematoma			



subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Tongue discolouration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Small intestinal haemorrhage			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	4	0	2
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Decubitus ulcer			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Ecchymosis			

subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Granulomatous dermatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Koilonychia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Onychalgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	1	0	3
Nail dystrophy			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Rash erythematous			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Rash macular			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Rash pruritic subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Skin mass subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Renal and urinary disorders			
Chronic kidney disease subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Acute kidney injury subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0	0 / 23 (0.00%) 0

Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	5 / 23 (21.74%)
occurrences (all)	0	0	5
Bursitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	2	0	2
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	0	0	3
Musculoskeletal chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Muscle spasms			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	1
Musculoskeletal pain			

subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Osteitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Vertebral osteophyte			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Spinal stenosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	2	0	1
Infections and infestations			
Appendicitis perforated			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	2	0	1
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	0	0	3
Clostridium difficile colitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Atypical pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0

Cystitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Erysipelas			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Furuncle			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Nasal herpes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0

Sepsis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	3 / 8 (37.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	4	0	1
Rash pustular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Septic shock			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Skin infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	1 / 23 (4.35%)
occurrences (all)	1	0	2
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	3
Viral pericarditis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0

Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Hypernatraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	3
Hyponatraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	2 / 8 (25.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	3 / 23 (13.04%)
occurrences (all)	1	0	3
Hypophosphataemia			



subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	2	0	0
Lactic acidosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Increased appetite			
subjects affected / exposed	1 / 8 (12.50%)	0 / 5 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0

<b>Non-serious adverse events</b>	Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d	Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d	Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	0 / 10 (0.00%)	12 / 12 (100.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	5	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Pallor			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Generalised oedema			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Early satiety			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	3 / 12 (25.00%)
occurrences (all)	3	0	3
Chest discomfort			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Hypothermia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Temperature intolerance			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1
Peripheral swelling			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Pyrexia			
subjects affected / exposed	4 / 11 (36.36%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	7	0	2
Oedema peripheral			

subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	3 / 12 (25.00%) 5
Thirst subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Reproductive system and breast disorders Genital rash subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Diaphragmalgia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Hypoxia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Haemoptysis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Pleural effusion			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dyspnoea exertional			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	2
Dysphonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	1	0	2
Sleep apnoea syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Sneezing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dysphoria			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Delirium			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Flat affect			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Phonophobia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Sleep terror			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			

subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Blast cell count increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	5	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Cardiac murmur			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	3	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	2	0	2
Troponin T increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	3 / 12 (25.00%)
occurrences (all)	7	0	6
Cataract operation complication			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Humerus fracture			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Post procedural swelling			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Periorbital haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Soft tissue injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Cardiac disorders			
Aortic valve incompetence			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Cardiomegaly			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1



Cardiac failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiac failure congestive			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Cardiac valve disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Bradycardia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiopulmonary failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Nervous system disorders			
Hypersomnia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	3
Dysgeusia			

subjects affected / exposed	4 / 11 (36.36%)	0 / 10 (0.00%)	5 / 12 (41.67%)
occurrences (all)	5	0	6
Dizziness			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Amnesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Peroneal nerve palsy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Parosmia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Parkinson's disease			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Lethargy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Nerve compression			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Migraine			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Presyncope			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Restless legs syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Sinus headache			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Toxic encephalopathy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 11 (45.45%)	0 / 10 (0.00%)	3 / 12 (25.00%)
occurrences (all)	26	0	8
Leukocytosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	5	0	0
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1
Thrombocytopenia subjects affected / exposed occurrences (all)	8 / 11 (72.73%) 29	0 / 10 (0.00%) 0	4 / 12 (33.33%) 8
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1
Vertigo subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Eye disorders			
Photophobia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Eye oedema subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1
Blepharitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Photopsia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1
Vision blurred			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	4 / 11 (36.36%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	6	0	2
Abdominal pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	3	0	2
Abdominal pain lower			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	6 / 11 (54.55%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	8	0	1
Abdominal mass			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Haematochezia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Flatulence			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hiatus hernia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Lip haemorrhage			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Oral mucosal blistering			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	3	0	2
Odynophagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Lip ulceration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Oral pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Retroperitoneal haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tongue discolouration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Small intestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	3	0	1
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Decubitus ulcer			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Ecchymosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Granulomatous dermatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Hyperkeratosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Koilonychia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Pyoderma gangrenosum			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Onychalgia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Pruritus			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	3	0	2
Nail dystrophy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash			



subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1
Rash erythematous			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	3	0	0
Rash pruritic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Acute kidney injury			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Renal failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Pollakiuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	2	0	2
Back pain			
subjects affected / exposed	4 / 11 (36.36%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	8	0	3
Arthralgia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1
Bursitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Intervertebral disc protrusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Myalgia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	4	0	0
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Muscular weakness			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Osteitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vertebral osteophyte			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Spinal stenosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Spinal osteoarthritis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	5	0	1
Infections and infestations			
Appendicitis perforated			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Clostridium difficile colitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Atypical pneumonia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Diverticulitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Erysipelas			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	4	0	0
Furuncle			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Nasal herpes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	5	0	1
Rash pustular			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	3	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Septic shock			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Spontaneous bacterial peritonitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Subcutaneous abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	3

Viral pericarditis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	4 / 11 (36.36%)	0 / 10 (0.00%)	2 / 12 (16.67%)
occurrences (all)	5	0	4
Hypernatraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hypermagnesaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Gout			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	4
Hyperuricaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lactic acidosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Increased appetite			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 February 2017	Major changes of Amendment (AM) 1 include editorial revisions and corrections to the Ph1/2a Initial Treatment Period transfusion language, restructuring/renumbering of the protocol document, and corrections to the Schedule of Assessments. These changes were instituted before the first participant was enrolled.
13 September 2017	Major changes of AM 2 include the reclassification of the "Reduction in spleen volume" from a secondary objective/endpoint to a primary objective/endpoint, as well as revisions to the eligibility criteria and revision of the DLT period to 7 days.
13 September 2017	Major changes of AM 3 include inclusion of a definition for clinical benefit and modifications to the titration and re-challenge rules.
21 May 2019	Major changes of AM 4 included the expansion of the study from a Phase 1/2a study to a Phase 2b study with addition of approximately 35 more participants, modification of the starting dose to 0.5 mg/kg/day, extension of the treatment period from 85 to 169 days with removal of the washout period, removal of pharmacokinetic and dose concentration sample collection requirements, and revision of some eligibility criteria.
22 January 2020	Major changes of AM 5 included modifications to the up-titration frequency, starting at ITP Day 14, addition of a Baseline run-in collection of Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score 24-HOUR recall, and addition of approximately 25 more participants.
15 December 2020	Major changes of AM 6 included modification of starting dose to 0.6 mg/kg/day, modification of some eligibility criteria, and prolongation of the time of first up-titration from ITP Day 14 to ITP Day 28.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported